Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial (Q83095982)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Elizabeth A Mittendorf

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Catherine E Storrer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Rebecca J Foley

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Katie Harris

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Yusuf Jama

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Craig D Shriver

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sathibalan Ponniah

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

George E Peoples

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

2309-2317

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

Peptides naturally presented by MHC class I molecules

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21849

7 January 2021

Identifiers

DOI

10.1002/CNCR.21849

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16596621%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference